Conatus Pharmaceuticals Inc. (CNAT) Reaches $5.24 After 9.00% Down Move; Nelson Van Denburg & Campbell Wealth Management Group Trimmed By $829,131 Its Amazon.Com (AMZN) Stake

June 20, 2018 - By Adrian Erickson

Amazon.com, Inc. (NASDAQ:AMZN) Logo

The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is a huge mover today! The stock decreased 2.42% or $0.13 during the last trading session, reaching $5.24. About 404,075 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has declined 29.66% since June 20, 2017 and is downtrending. It has underperformed by 42.23% the S&P500. Some Historical CNAT News: ; 04/04/2018 – Conatus Pharmaceuticals: Treatment Effect in Subgroup of Patients Supports Further Evaluation; 04/04/2018 – CONATUS REPORTS TOP-LINE FROM PHASE 2B POLT-HCV-SVR TRIAL; 30/04/2018 – Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis an; 04/04/2018 – CONATUS PHARMACEUTICALS INC – BIOPSY-BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION; 05/04/2018 – Conatus Closes Below 200-Day Moving Average: Technicals; 04/04/2018 – CONATUS PHARMACEUTICALS INC – ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019; 04/04/2018 – CONATUS: POLT-HCV-SVR TRIAL DID NOT MEET PRIMARY ENDPOINT; 18/04/2018 – Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo; 04/04/2018 – Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial; 18/04/2018 – Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In VivoThe move comes after 5 months negative chart setup for the $157.53M company. It was reported on Jun, 20 by Barchart.com. We have $4.77 PT which if reached, will make NASDAQ:CNAT worth $14.18M less.

Nelson Van Denburg & Campbell Wealth Management Group Llc decreased Amazon.Com Inc (AMZN) stake by 16.76% reported in 2018Q1 SEC filing. Nelson Van Denburg & Campbell Wealth Management Group Llc sold 573 shares as Amazon.Com Inc (AMZN)’s stock rose 5.80%. The Nelson Van Denburg & Campbell Wealth Management Group Llc holds 2,845 shares with $4.12M value, down from 3,418 last quarter. Amazon.Com Inc now has $849.58B valuation. The stock increased 0.93% or $16.12 during the last trading session, reaching $1750.9. About 3.43 million shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 62.09% since June 20, 2017 and is uptrending. It has outperformed by 49.52% the S&P500. Some Historical AMZN News: ; 20/04/2018 – James Comey will visit Amazon on Monday for a fireside chat with employees. via @cnbctech; 15/03/2018 – Jessica Toonkel: Exclusive: Amazon’s internal numbers on Prime Video, revealed GREAT SCOOP by @jldastin; 01/05/2018 – Sabre announces strategic relationship with Amazon Web Services to accelerate the evolution of travel technology; 09/05/2018 – GovTechUS: Google, Amazon, Facebook Set to Discuss AI at White House; 10/04/2018 – MEDIA-Amazon ups ante in Walmart-Flipkart deal talks with breakup fee of up to $2 bln- FactorDaily; 10/04/2018 – Variety: Amazon to Partner With Mobile Operators to Grow Media Services Worldwide; 18/04/2018 – Amazon’s Alexa in TVs: A Route Around Google, Says Morgan Stanley — Barron’s Blog; 18/04/2018 – Amazon, Best Buy forge `smart TV’ pact; 02/05/2018 – Synchrony Teams with Amazon to Introduce New Alexa Skill for Amazon Store Card; 05/03/2018 – Bloomberg Asia: Amazon is planning to expand Whole Foods delivery to San Francisco

Investors sentiment decreased to 1.08 in Q1 2018. Its down 0.21, from 1.29 in 2017Q4. It dived, as 73 investors sold AMZN shares while 659 reduced holdings. 173 funds opened positions while 614 raised stakes. 266.38 million shares or 4.87% less from 280.02 million shares in 2017Q4 were reported. Jnba owns 0.01% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 626 shares. Capital City Fl has 1.46% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 2,341 shares. Deroy And Devereaux Private Inv Counsel Inc accumulated 567 shares. Ingalls Snyder Ltd Liability Company owns 1,481 shares for 0.1% of their portfolio. -based Farr Miller Washington Limited Company Dc has invested 0.13% in Amazon.com, Inc. (NASDAQ:AMZN). Marathon Asset Mgmt Llp holds 51,408 shares or 1.15% of its portfolio. Newfocus Group Inc Limited Liability Company reported 184 shares or 0.17% of all its holdings. Da Davidson & has 12,962 shares for 0.39% of their portfolio. Stonebridge Mgmt, a California-based fund reported 959 shares. Adage Prtnrs Grp Ltd Limited Liability Company invested 1.81% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN). Naples Glob Ltd Liability Corporation has invested 0.39% in Amazon.com, Inc. (NASDAQ:AMZN). Harvey Capital stated it has 2.74% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN). Delta Asset Management Lc Tn holds 584 shares or 0.13% of its portfolio. Beck Mgmt Limited Liability Co holds 4.54% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN) for 6,819 shares. Virtu Fincl owns 0.04% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 523 shares.

Among 55 analysts covering Amazon.com (NASDAQ:AMZN), 52 have Buy rating, 0 Sell and 3 Hold. Therefore 95% are positive. Amazon.com had 305 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Buy” rating given on Wednesday, March 14 by Piper Jaffray. RBC Capital Markets maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, February 3. RBC Capital Markets has “Outperform” rating and $900 target. Piper Jaffray maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, July 24. Piper Jaffray has “Overweight” rating and $650 target. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Buy” rating given on Thursday, September 22 by Argus Research. Morgan Stanley maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, August 28. Morgan Stanley has “Overweight” rating and $740 target. Canaccord Genuity maintained it with “Buy” rating and $1200.0 target in Wednesday, October 11 report. The company was maintained on Monday, February 12 by DA Davidson. The rating was upgraded by Monness on Friday, October 27 to “Buy”. Axiom Capital maintained Amazon.com, Inc. (NASDAQ:AMZN) on Monday, December 28 with “Buy” rating. Credit Suisse maintained Amazon.com, Inc. (NASDAQ:AMZN) on Friday, October 23 with “Outperform” rating.

More notable recent Amazon.com, Inc. (NASDAQ:AMZN) news were published by: 247Wallst.com which released: “Amazon Hub Wants to Handle Every Package You Get” on June 19, 2018, also Nasdaq.com with their article: “Roku Really Wants to Compete With Big Cable” published on June 20, 2018, Nasdaq.com published: “A Safe Dividend Makes Verizon Communications Inc. Stock a Safe Bet” on June 19, 2018. More interesting news about Amazon.com, Inc. (NASDAQ:AMZN) were released by: Seekingalpha.com and their article: “iQiyi: 2 Reasons The Run Can Continue” published on June 20, 2018 as well as Nasdaq.com‘s news article titled: “Better Buy: Amazon.com vs. Google” with publication date: June 17, 2018.

Analysts await Amazon.com, Inc. (NASDAQ:AMZN) to report earnings on July, 26. They expect $2.52 EPS, up 530.00% or $2.12 from last year’s $0.4 per share. AMZN’s profit will be $1.22 billion for 173.70 P/E if the $2.52 EPS becomes a reality. After $3.27 actual EPS reported by Amazon.com, Inc. for the previous quarter, Wall Street now forecasts -22.94% negative EPS growth.

Nelson Van Denburg & Campbell Wealth Management Group Llc increased Vanguard High Dividend Yield (VYM) stake by 5,308 shares to 84,120 valued at $6.94 million in 2018Q1. It also upped Verizon Communications (NYSE:VZ) stake by 16,426 shares and now owns 47,040 shares. Johnson & Johnson Com (NYSE:JNJ) was raised too.

Since February 15, 2018, it had 0 insider buys, and 21 selling transactions for $63.19 million activity. On Friday, May 4 the insider WILKE JEFFREY A sold $947,950. The insider ALBERG TOM A sold $3.35 million. 1,375 shares valued at $2.17 million were sold by STONESIFER PATRICIA Q on Wednesday, May 2. $2.72 million worth of Amazon.com, Inc. (NASDAQ:AMZN) was sold by Jassy Andrew R on Tuesday, May 15. The insider Olsavsky Brian T sold $3.22M. Zapolsky David had sold 2,216 shares worth $3.24M. 12,666 Amazon.com, Inc. (NASDAQ:AMZN) shares with value of $18.50 million were sold by Blackburn Jeffrey M.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on August, 1. They expect $-0.20 EPS, down 5.26% or $0.01 from last year’s $-0.19 per share. After $-0.17 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 17.65% negative EPS growth.

Among 7 analysts covering Conatus Pharma (NASDAQ:CNAT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 17 analyst reports since September 22, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) on Thursday, August 3 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 22. H.C. Wainwright maintained the shares of CNAT in report on Thursday, June 29 with “Buy” rating. The company was maintained on Tuesday, December 20 by H.C. Wainwright. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Oppenheimer on Wednesday, March 7. The rating was initiated by Oppenheimer with “Buy” on Thursday, March 1. The firm has “Buy” rating given on Thursday, March 22 by Oppenheimer. Stifel Nicolaus maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) on Thursday, November 5 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Tuesday, December 20 with “Buy”. Roth Capital initiated the stock with “Buy” rating in Friday, July 1 report.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $157.53 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

More news for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were recently published by: Seekingalpha.com, which released: “Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?” on June 03, 2018. Seekingalpha.com‘s article titled: “Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?” and published on June 01, 2018 is yet another important article.

Investors sentiment increased to 1.11 in Q1 2018. Its up 0.01, from 1.1 in 2017Q4. It is positive, as 6 investors sold Conatus Pharmaceuticals Inc. shares while 22 reduced holdings. 12 funds opened positions while 19 raised stakes. 11.99 million shares or 2.38% more from 11.71 million shares in 2017Q4 were reported. Goldman Sachs Gru Inc owns 87,520 shares or 0% of their US portfolio. Wellington Mgmt Group Limited Liability Partnership holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 48,054 shares. Jpmorgan Chase & holds 74,062 shares or 0% of its portfolio. California Public Employees Retirement Systems owns 24,900 shares. Acadian Asset Management Ltd Llc reported 0.01% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Bridgeway Capital Management Inc holds 136,300 shares. Ellington Mgmt Ltd Liability Company holds 0.03% or 60,600 shares in its portfolio. Arrowstreet Cap Ltd Partnership stated it has 124,064 shares or 0% of all its holdings. American Century Inc holds 109,571 shares or 0% of its portfolio. Art Lc holds 11,613 shares or 0% of its portfolio. Fincl Architects Inc accumulated 0% or 1,600 shares. State Of Wisconsin Inv Board invested in 20,000 shares or 0% of the stock. 96,765 are held by Qs Investors Limited Liability Corporation. Gp One Trading Limited Partnership has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Millennium Mgmt Limited Liability has invested 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT).

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.